RATIONALE AND OBJECTIVES: The purpose of this study was to compare different contrast agents for longitudinal liver and spleen imaging in a mouse model of liver metastasis. MATERIALS AND METHODS: Mice developing liver metastases underwent longitudinal micro-computed tomography imaging after injection of Fenestra LC, ExiTron nano 6000, or ExiTron nano 12000. Elimination times and contrast enhancement of liver and spleen were compared. RESULTS: For all contrast agents, liver contrast peaked at approximately 4 hours and spleen contrast at 48 hours postinjection. A single dose of 100 μL of ExiTron nano 6000 or 12000 resulted in longstanding enhancement of liver and spleen tissue for longer than 3 weeks, whereas repeated injections of 400 μL of Fenestra LC were required to retain contrast at acceptable levels and allowed imaging of the liver/spleen for up to 2 and 9 days, respectively. CONCLUSION: Both ExiTron nano agents provide longer and stronger contrast enhancement of liver and spleen compared to Fenestra LC, and they do so at a 75% lower injection volume in mice.
RATIONALE AND OBJECTIVES: The purpose of this study was to compare different contrast agents for longitudinal liver and spleen imaging in a mouse model of liver metastasis. MATERIALS AND METHODS:Mice developing liver metastases underwent longitudinal micro-computed tomography imaging after injection of Fenestra LC, ExiTron nano 6000, or ExiTron nano 12000. Elimination times and contrast enhancement of liver and spleen were compared. RESULTS: For all contrast agents, liver contrast peaked at approximately 4 hours and spleen contrast at 48 hours postinjection. A single dose of 100 μL of ExiTron nano 6000 or 12000 resulted in longstanding enhancement of liver and spleen tissue for longer than 3 weeks, whereas repeated injections of 400 μL of Fenestra LC were required to retain contrast at acceptable levels and allowed imaging of the liver/spleen for up to 2 and 9 days, respectively. CONCLUSION: Both ExiTron nano agents provide longer and stronger contrast enhancement of liver and spleen compared to Fenestra LC, and they do so at a 75% lower injection volume in mice.
Authors: Stefanie Kirschner; Manuela C Felix; Linda Hartmann; Miriam Bierbaum; Máté E Maros; Hans U Kerl; Frederik Wenz; Gerhard Glatting; Martin Kramer; Frank A Giordano; Marc A Brockmann Journal: J Neurooncol Date: 2015-01-22 Impact factor: 4.130
Authors: Diana Groza; Sebastian Gehrig; Pavol Kudela; Martin Holcmann; Christine Pirker; Carina Dinhof; Hemma H Schueffl; Marek Sramko; Julia Hoebart; Fatih Alioglu; Michael Grusch; Manfred Ogris; Werner Lubitz; Bernhard K Keppler; Irena Pashkunova-Martic; Christian R Kowol; Maria Sibilia; Walter Berger; Petra Heffeter Journal: Oncoimmunology Date: 2018-02-16 Impact factor: 8.110
Authors: Paul Flechsig; Clemens Kratochwil; Arne Warth; Daniel Rath; Viktoria Eichwald; Peter E Huber; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel Journal: Mol Imaging Biol Date: 2016-04 Impact factor: 3.488
Authors: Manuela C Felix; Jens Fleckenstein; Stefanie Kirschner; Linda Hartmann; Frederik Wenz; Marc A Brockmann; Gerhard Glatting; Frank A Giordano Journal: PLoS One Date: 2015-05-19 Impact factor: 3.240
Authors: Mihaela Ignat; Cherif Youssef Akladios; Véronique Lindner; Konstantin Khetchoumian; Marius Teletin; Didier Muttter; Pierre Marc Aprahamian; Jacques Marescaux Journal: J Exp Clin Cancer Res Date: 2016-09-29